NCT00302016No Longer Available不适用
An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 59
研究概览
简要总结
This study will further evaluate if AMN107 is safe in adults with chronic myeloid leukemia who are resistant or intolerant to imatinib and to provide patients access to this new drug until the drug becomes commercially available.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (59)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate TherapyLeukemia, Myeloid, ChronicNCT00264160Novartis Pharmaceuticals36
已完成
4 期
Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 TrialChronic Myelogenous LeukemiaNCT01368523Novartis Pharmaceuticals19
已完成
不适用
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseLeukemia, Myeloid, ChronicNCT00538109King Faisal Specialist Hospital & Research Center8
已完成
4 期
Intensive compared with nonintensive chemotherapy in treating older patients with acute myeloid leukaemia or myelodysplastic syndromeAcute myeloid leukaemia or high-risk myelodysplastic syndromeMyeloid leukaemiaCancerISRCTN62207270eukaemia Research Fund (UK)217
终止
2 期
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)Myeloid Leukemia, ChronicMyeloid Leukemia, Chronic, Accelerated-PhaseBlast PhaseMyeloid Leukemia, Chronic, Chronic-PhaseNCT00114959ChemGenex Pharmaceuticals15